Author(s): Abramowitz L, Mathieu N, RoudotThoraval F, Lemarchand N, Bauer P, , Abramowitz L, Mathieu N, RoudotThoraval F, Lemarchand N, Bauer P,
Abstract Share this page
Abstract BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients. AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era. METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004. RESULTS: In all, 151 patients (44 HIV+, 107 HIV-) were reviewed retrospectively for 27 (median of 16-44) months. HIV+ patients were male (100\% vs. 27\%, P < 0.001) and younger (45 vs. 62 years old, P < 0.001) than HIV- patients. No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status. After chemoradiotherapy, similar numbers of HIV+ and HIV- patients had grade III-IV toxicity. A complete response was obtained in 82\% and 75\% (N.S.) of cases, respectively. The disease-free survival rates were 77\% and 67\% (N.S.) and the overall survival rates were 85\% and 84\% (N.S.), respectively, after 3 years of follow-up. Duration of HIV infection, viral load and CD4 count had no effect on the survival rate of HIV+ patients with EAC. CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients. Therefore, the same therapeutic guidelines should be applied to both populations.
This article was published in Aliment Pharmacol Ther
and referenced in Journal of AIDS & Clinical Research